实用临床医药杂志2025，Vol.29Issue(10)：46-51,6.DOI:10.7619/jcmp.20245143
特瑞普利单抗联合经支气管动脉化疗栓塞和调强放疗对晚期肺癌的效果评价
Efficacy of toripalimab combined with bronchial arterial chemoembolization and intensity-modulated radiotherapy in advanced lung cancer
摘要
Abstract
Objective To observe the clinical efficacy of toripalimab combined with bronchial ar-terial chemoembolization(BACE)and intensity-modulated radiotherapy(IMRT)in advanced lung cancer.Methods A prospective single-arm trial was conducted in 104 patients with programmed death-ligand 1(PD-L1)-positive,driver gene-negative non-small cell lung cancer(NSCLC)in stages of Ⅲ B to Ⅳ admitted to the First People's Hospital of Guangyuan City of Sichuan Province.All patients received toripalimab combined with BACE and IMRT.Clinical efficacy,symptom improve-ment time,tumor biomarker levels[carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),cytokeratin 19 fragment(CYFRA21-1),neuron-specific enolase(NSE)],T-lymphocyte subsets(CD3+,CD4+,CD4+/CD8+),survival outcomes,and adverse events were analyzed.Results Among 102 patients,the objective response rate(ORR)was 75.49％,disease control rate(DCR)was 90.20％,survival rate was 68.63％,and 12-month progression-free survival rate was 62.75％.The overall incidence of adverse events of any grade was 72.55％.Post-BACE,post-IMRT,and post-toripalimab treatment levels of CEA,CYFRA21-1,CA199,and NSE were significantly lower than baseline data(P＜0.05),with the lowest levels observed after toripalimab treatment compared to post-BACE and post-IMRT(P＜0.05).CD3+,CD4+,and CD4+/CD8+decreased after BACE,IMRT and toripalimab therapy,but they were increased following toripalimab therapy compared with the other two therapies(P＜0.05).Conclusion Toripalimab combined with BACE and IMRT demonstrates significant clinical efficacy and acceptable tolerability in PD-L1-positive,driver gene-negative NSCLC in stages of ⅢB to Ⅳ,serving as a preferred consolidation regimen after unresect-able chemoradiotherapy.关键词
程序性死亡受体配体1/非小细胞肺癌/支气管动脉栓塞/调强放射治疗/特瑞普利单抗/肿瘤标志物/T淋巴细胞亚群/生存期Key words
programmed death-ligand 1/non-small cell lung cancer/bronchial arterial che-moembolization/intensity-modulated radiotherapy/toripalimab/tumor biomarkers/T-lymphocyte subsets/survival period分类
临床医学引用本文复制引用
孙铭强,袁瑛,展静静,唐珊..特瑞普利单抗联合经支气管动脉化疗栓塞和调强放疗对晚期肺癌的效果评价[J].实用临床医药杂志,2025,29(10):46-51,6.基金项目
四川省医学(青年创新)科研课题项目(S19182) （青年创新）
